Coherus Oncology (CHRS) Operating Leases (2019 - 2026)
Coherus Oncology (CHRS) posted Operating Leases of $954000.0 for Q1 2026, down 34.52% sequentially from $1.5 million in Q4 2025, and down 66.57% YoY from $2.9 million in Q1 2025.
Coherus Oncology (CHRS) Operating Leases (2019 - 2026) Analysis & Trends
Coherus Oncology has reported Operating Leases for 8 years, with the latest figure at $954000.0 in Q1 2026.
- Quarterly Operating Leases fell 66.57% year-over-year to $954000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $954000.0 (down 66.57% YoY) and the FY2025 annual result came in at $1.5 million, down 55.66% from the prior year.
- Operating Leases declined to $954000.0 in Q1 2026 per CHRS's latest filing, from $1.5 million in the prior quarter.
- Over five years, Operating Leases peaked at $6.8 million in Q2 2022 and troughed at $954000.0 in Q1 2026.
- A 5-year average of $3.7 million and a median of $3.7 million in 2024 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2023 and 2024: Operating Leases slumped 76.55% in 2023, then jumped 160.24% in 2024.
- Over 5 years, Operating Leases stood at $5.0 million in 2022, then advanced by 5.59% to $5.3 million in 2023, then tumbled by 38.33% to $3.3 million in 2024, then sank by 55.66% to $1.5 million in 2025, then sank by 34.52% to $954000.0 in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $954000.0, $1.5 million, and $1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 459,000.00 |
| Mar 31, 2026 | 954,000.00 |
| Dec 31, 2025 | 1.46 Mn |
| Sep 30, 2025 | 1.95 Mn |
| Jun 30, 2025 | 2.41 Mn |
| Mar 31, 2025 | 2.85 Mn |
| Dec 31, 2024 | 3.29 Mn |
| Sep 30, 2024 | 3.74 Mn |
| Jun 30, 2024 | 4.17 Mn |
| Mar 31, 2024 | 4.68 Mn |
| Dec 31, 2023 | 5.33 Mn |
| Sep 30, 2023 | 1.44 Mn |
| Jun 30, 2023 | 2.62 Mn |
| Mar 31, 2023 | 3.81 Mn |
| Dec 31, 2022 | 5.05 Mn |
| Sep 30, 2022 | 6.12 Mn |
| Jun 30, 2022 | 6.81 Mn |
| Mar 31, 2022 | 6.52 Mn |
| Dec 31, 2021 | 7.25 Mn |
| Sep 30, 2021 | 7.97 Mn |